Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2014; 20(31): 10668-10681
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10668
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10668
Recurrent hepatitis C after liver transplant
Andrew S deLemos, Paul A Schmeltzer, Mark W Russo, Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC 28232-2861, United States
Author contributions: deLemos AS, Schmeltzer PA and Russo MW wrote the paper.
Correspondence to: Mark W Russo, MD, MPH, Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, 1000 Blythe Blvd, Charlotte, NC 28232-2861, United States. mark.russo@carolinashealthcare.org
Telephone: +1-704-3551279 Fax: +1-704-4464877
Received: November 13, 2013
Revised: January 25, 2014
Accepted: April 2, 2014
Published online: August 21, 2014
Processing time: 280 Days and 6.7 Hours
Revised: January 25, 2014
Accepted: April 2, 2014
Published online: August 21, 2014
Processing time: 280 Days and 6.7 Hours
Core Tip
Core tip: Recurrent hepatitis C impacts graft and patient survival following liver transplant. Preventing aggressive hepatitis C virus (HCV) recurrence by selecting appropriate donor allografts for HCV patients and careful management of immunosuppression in the post-transplant setting remain crucial. Direct acting antiviral therapy in patients awaiting transplant may prevent HCV re-infection post-transplant and has the potential to fundamentally change the natural history of hepatitis C in liver transplant recipients.